期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

单克隆抗体在肿瘤治疗中应用的研究进展 被引量：8

Progress of clinical application of monoclonal antibodies in the treatment of cancer
暂未订购
导出
摘要 近年来 ,随着生物技术在医学领域的快速发展 ,单克隆抗体在肿瘤的临床治疗中也取得了长足的进步。本文简略介绍目前处于临床Ⅲ期研究中的几个单抗并重点讨论了已上市的三个单抗herceptin、rituxan(rituximab)和panorex(mAb17 1A)在乳腺癌、淋巴瘤和结 直肠癌治疗中的作用 。 As biotechnology has developed so rapidly during recent years, the clinical application of monoclonal antibody in the treatment of cancer has achieved great success. This article briefly introduces the current status of several monoclonal antibodies in phase Ⅲ clinical trials and discusses in detail three monoclonal antibodies (herceptin, rituxan, panorex) in the treatment of breast cancer, malignant lymphoma and colorectal cancer, respectively. Thus, the clinicians will have updated information in monoclonal antibody development.
作者 储大同
机构地区 中国医学科学院肿瘤医院内科
出处 《中国癌症杂志》 CAS CSCD 2001年第5期409-415,共7页 China Oncology
关键词 单克隆抗体 肿瘤 治疗 monoclonic antibody tumors therapy
分类号 R730.54 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1[1]Miller RA. Treatmcnt of B-cell lymphoma with monoclonal anti-idiotype antibody[J].New Engl J Med,1982,306(9):517-522.
  • 2[2]Cobleigh M. Efficacy and safety of herceptin (humanized anti-HER-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer[J].Proc Am Soc Clin Oncol,1998,17:376.
  • 3[3]Slamon DJ,Leyland-Jones B,Shak S,et al. Addition of herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anti-cancer activity[J].Proc Am Soc Clin Oncol,1998,17:377.
  • 4[4]Seidman AD,Fornier M,Esteva F,et al. Final report: weekly herceptin and taxol for metastatic breast cancer: analysis of efficacy by HER-2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)][J].Proc Am Soc Clin Oncol,2000,19:319.
  • 5[5]Nicholson BP,Thor AD,Goldstein LJ,et al. Weekly docetaxel and rhumabher combination therapy as first or second line treatment for metastatic breast cancer[J].Proc Am Soc Clin Oncol,2000,19:549.
  • 6[6]Burstein HJ,Kuter I,Richardson PG,et al. Herceptin and vinorelbine for HER-2 positive metastatic breast cancer: a phase Ⅱ study[J].Proc Am Soc Clin Oncol,2000,19:392.
  • 7[7]Maloney D,Grillo-Lopez A,White C,et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma[J].Blood,1997,90(6):2188-2195.
  • 8[8]McLaughlin P,Grillo-Lopez A,Link B,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program[J].J Clin Oncol,1998,16(8):2825-2833.
  • 9[9]Piro L,White C,Grillo-Lopez A,et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma[J].Ann Oncol,1999,10(6):655-661.
  • 10[10]Davis T,White C,Grillo-Lopez A,et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase Ⅱ trial of rituximab[J].J Clin Oncol,1999,17(6):1851-1857.

同被引文献105

引证文献8

二级引证文献17

中国癌症杂志
2001年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部